Maharashtra FDA Cancels Drug Sale Licences of Cipla’s Logistics Unit in Pune Over Regulatory Violations
Detailed Overview of the Regulatory Action
The Maharashtra Food and Drug Administration (FDA) has taken a major enforcement step by cancelling the drug sale licences of Cipla Pharma & Life Sciences Ltd.’s Carry and Forwarding (C&F) facility located at Wadki, Pune. This action follows an intensive investigation into regulatory non-compliance involving high-risk prescription medicines.
What Triggered the Investigation?
The investigation began in June 2026 when FDA officials inspected stocks of Reactin Plus Tablets, a Schedule H prescription medicine. The regulator found that the packaging contained unauthorized promotional wording, describing the product as an “analgesic and antipyretic.” Such claims are restricted under the Drugs and Cosmetics Act, 1940, as they may encourage unsupervised use of prescription drugs.
Impact on Product Stock
Following the inspection, the FDA seized stocks of Reactin Plus Tablets worth approximately ₹11.19 Lakh. The regulator emphasized that proper pharmaceutical warehousing is critical to prevent moisture exposure, physical damage, and mix-ups.
Important Clarification for Pharmacy Students
It is crucial to note that this action relates specifically to the Pune C&F establishment and not a nationwide ban. Cipla has clarified that the order does not allege concerns regarding the safety, quality, or efficacy of the products themselves, but focuses on logistics and regulatory compliance.
